Natalizumab in the pediatric MS population: results of the Italian registry

• Published in: BMC neurology Vol. 15; no. 1; p. 174
• Main Authors: Ghezzi, Angelo, Moiola, Lucia, Pozzilli, Carlo, Brescia-Morra, Vincenzo, Gallo, Paolo, Grimaldi, Luigi Maria Edoardo, Filippi, Massimo, G., Giancarlo Comi
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 25.09.2015; BioMed Central
• Subjects: Adolescent; Care and treatment; Child; Complications and side effects; Female; Glatiramer Acetate - therapeutic use; Health aspects; Humans; Interferon; Interferon-beta - therapeutic use; Italy; Magnetic Resonance Imaging; Male; Multiple sclerosis; Multiple Sclerosis - drug therapy; Natalizumab - therapeutic use; Pediatrics; Pharmaceutical industry; Planning; Recurrence; Registries; Italy; Israel; France; United States; Switzerland; Germany

Natalizumab is a promising option for pediatric multiple sclerosis (MS) patients with active evolution and a poor response to Interferon-beta or Glatiramer Acetate. However, no data are available in large cohorts of patients and after a long-term follow up. Our study was planned to shed lights on th...